Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid Tumors

Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures